Arcellx Overview

  • Founded
  • 2014
Founded
  • Status
  • Public
  • Employees
  • 74
Employees
  • Stock Symbol
  • ACLX
Stock Symbol
  • Share Price
  • $17.18
  • (As of Monday Closing)

Arcellx General Information

Description

Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases.

Contact Information

Website
www.arcellx.com
Formerly Known As
Encarta Therapeutics
Ownership Status
Publicly Held
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Other Healthcare Technology Systems
Biotechnology
Stock Exchange
NAS
Primary Office
  • 25 West Watkins Mill Road
  • Suite A
  • Gaithersburg, MD 20878
  • United States
+1 (240) 000-0000

Arcellx Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Arcellx Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$17.18 $18.00 $15.55 - $19.93 $626M 34.8M 203K -$5.72

Arcellx Financials Summary

In Thousands,
USD 		TTM 30-Sep-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
Revenue 0 0 0
EBITDA (52,517) (31,466) (17,646)
Net Income (53,392) (32,095) (17,972)
Total Assets 144,963 57,694 43,588
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Arcellx Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Arcellx‘s full profile, request access.

Request a free trial

Arcellx Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion
Price		 % Owned

This information is available in the PitchBook Platform. To explore Arcellx‘s full profile, request access.

Request a free trial

Arcellx Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of innovative imm
Drug Discovery
Gaithersburg, MD
74 As of 2022
00000
0000 0000-00-00
00000000 00000

00000 00

uis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur
0000 000000000
South San Francisco, CA
00 As of 0000
00000
000000000 00000

00000000

tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitati
0000 000000000
Seattle, WA
00 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Arcellx Competitors (5)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Senti Bio Venture Capital-Backed South San Francisco, CA 00 00000 000000000 00000
000000000000 Venture Capital-Backed Seattle, WA 00 00000 000000000 00000
0000000 00000000 Formerly VC-backed Cambridge, MA 00 00000 000000 - 000 00000
0000000 0000000000 Formerly VC-backed Berkeley, CA 00 00000 00000000 00000
00000 000000000 Formerly VC-backed South San Francisco, CA 000 00000 000000 - 000 00000
You’re viewing 5 of 5 competitors. Get the full list »

Arcellx Patents

  • 5

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 000

    Granted

  • 1

    Pending

  • 000

    Expiring in next 12 mo

Arcellx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2018368431-A1 Multifunctional immune cell therapies Pending 14-Nov-2017 00000000000
JP-2021503006-A Multifunctional immune cell therapy Pending 14-Nov-2017 000000000
CA-3082410-A1 Multifunctional immune cell therapies Pending 14-Nov-2017 000000000
EP-3710034-A1 Multifunctional immune cell therapies Pending 14-Nov-2017 000000000
US-20210023133-A1 Multifunctional immune cell therapies Pending 14-Nov-2017 A61K35/17
To view Arcellx’s complete patent history, request access »

Arcellx Executive Team (13)

Name Title Board Seat Contact Info
Rami Elghandour Chief Executive Officer & Chairman
Michael Dombeck Chief Operating Officer
David Hilbert Ph.D Founder & Chief Technology Officer
Narinder Singh Chief Technology Officer
Narinderjeet Singh Chief Technology Officer, Technology
You’re viewing 5 of 13 executive team members. Get the full list »

Arcellx Board Members (14)

Name Representing Role Since
Ali Behbahani MD Self Board Member 000 0000
Ali Behbahani Self Board Member 000 0000
David Lubner Self Board Member 000 0000
Derek Yoon AJU IB Investment Board Member 000 0000
Jill Carroll Self Board Member 000 0000
You’re viewing 5 of 14 board members. Get the full list »

Arcellx Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Arcellx Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Arcellx‘s full profile, request access.

Request a free trial